ALPM.F Stock Overview
Manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Astellas Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥9.90 |
| 52 Week High | JP¥12.74 |
| 52 Week Low | JP¥9.13 |
| Beta | 0.16 |
| 1 Month Change | 4.21% |
| 3 Month Change | -1.00% |
| 1 Year Change | -7.82% |
| 3 Year Change | -36.98% |
| 5 Year Change | -23.85% |
| Change since IPO | -66.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALPM.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.3% | -3.9% | -2.2% |
| 1Y | -7.8% | -0.04% | 9.6% |
Return vs Industry: ALPM.F underperformed the US Pharmaceuticals industry which returned -0.1% over the past year.
Return vs Market: ALPM.F underperformed the US Market which returned 9.5% over the past year.
Price Volatility
| ALPM.F volatility | |
|---|---|
| ALPM.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: ALPM.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ALPM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 14,754 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Astellas Pharma Inc. Fundamentals Summary
| ALPM.F fundamental statistics | |
|---|---|
| Market cap | US$17.68b |
| Earnings (TTM) | -US$386.33m |
| Revenue (TTM) | US$12.56b |
1.4x
P/S Ratio-45.8x
P/E RatioIs ALPM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPM.F income statement (TTM) | |
|---|---|
| Revenue | JP¥1.87t |
| Cost of Revenue | JP¥345.58b |
| Gross Profit | JP¥1.52t |
| Other Expenses | JP¥1.58t |
| Earnings | -JP¥57.43b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -32.08 |
| Gross Margin | 81.50% |
| Net Profit Margin | -3.07% |
| Debt/Equity Ratio | 61.3% |
How did ALPM.F perform over the long term?
See historical performance and comparisonDividends
5.0%
Current Dividend Yield-225%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 23:52 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Astellas Pharma Inc. is covered by 30 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hazim Bahari | CFRA Equity Research |